According to a GlobalData report, the market for bariatric surgery is moving away from gastric bands and toward balloons.

Known as "MediPoint: Bariatric Medical procedure Gadgets - Worldwide Examination and Market Gauges', the report assesses the bariatric medical procedure market to develop at a build yearly development pace of 7.1% across 39 nations.

"The key drivers for the growth include the rising prevalence of obesity, advancements in bariatric procedures, and the emergence of procedures that are minimally invasive and non-invasive."
The bariatric medical procedure market, which incorporates bariatric stapling gadgets, gastric groups and gastric inflatables, is supposed to increment from $1.1bn in 2016 to $1.9bn by 2023. The critical drivers for the development incorporate the rising predominance of corpulence, progressions in bariatric techniques and appearance of negligibly obtrusive and harmless methodology.
According to Brigitte Babin, MSc, GlobalData's Analyst for Medical Devices, the most common surgeries in the bariatric industry are sleeve gastrectomy and gastric bypass, both of which are carried out with the help of bariatric stapling devices. The demand for bariatric stapling devices and, consequently, the market for bariatric surgery devices is expected to rise annually as a result of these procedures.

On the other hand, the gastric bands and balloons pipeline product Market, which includes gastric bands and gastric balloons, has been experiencing divergent trends. Long-term studies have revealed complications following gastric banding procedures, which is expected to reduce the gastric band market. Though the gastric inflatables fragment is supposed to observe fast development as it is a non-careful, less obtrusive and a momentary treatment choice, Babin adds.

Medtronic and Ethicon Endo-surgery, two major players, hold approximately 85% of the Medtronic and Ethicon Endo-surgery market share. The two organizations are supposed to proceed with their market strength, while more modest players like Apollo Endosurgery, Cousin Biotech and ReShape will represent the excess piece of the pie.